We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Lymphocytes
- Lymphomas
- Nodal vs. cutaneous lymphoma
- WHO classification (revised 4th ed., 2017/18)
- New lymphoma classifications
- Primary cutaneous lymphomas (1)
- Diagnosis in cutaneous lymphomas
- Differential diagnosis (1)
- Diagnostic approach to cutaneous lymphomas
- Primary cutaneous lymphomas (2)
- Mycosis fungoides (MF)
- Mycosis fungoides: phenotype
- Mycosis fungoides:patch stage (early MF)
- Drug eruption mimicking CD8-positive MF
- T-cell clonality in cutaneous T-cell lymphomas
- T-cell clonality in early MF
- Mycosis fungoides: variants & subforms
- Follicular mycosis fungoides
- Granulomatous slack skin
- Pagetoid reticulosis (Woringer Kolopp disease)
- Mycosis fungoides evolution
- Mycosis fungoides tumor stage
- Mycosis fungoides: large cell transformation
- Mycosis fungoides: prognostic markers
- MF stage adapted treatment strategy
- Mycosis fungoides and Sézary syndrome: therapy
- Primary cutaneous lymphomas (3)
- Primary cutaneous CD30+ lymphoproliferative disorders
- Lymphomatoid papulosis (LyP)
- LyP: histological types (WHO classification 2018)
- LyP: WHO classification 2017
- LyP types: differential diagnosis
- LyP type A
- Cutaneous involvement by Hodgkin lymphoma
- Scabies
- LyP type B
- LyP type C
- Differential diagnosis (2)
- Angioinvasive LyP (type E)
- Differential diagnosis (3)
- LyP: therapeutic strategy
- LyP: course and prognosis
- Primary cutaneous anaplastic large cell lymphoma (PC-ALCL)
- Primary cutaneous vs. systemic ALCL
- ALCL subtypes
- Large CD30+ tumor cells: differential diagnosis
- The large cell dilemma
- Differential diagnosis (4)
- C-ALCL: course and prognosis
- C- ALCL treatment
- Brentuximab vedotin in cutaneous CD30+ LPD
- CD30 evaluation in cutaneous lymphomas
- Sézary syndrome (1)
- Sézary syndrome: histology
- Erythroderma: differential diagnosis
- Sézary syndrome (2)
- Sézary syndrome: diagnostic criteria
- Cutaneous lymphomas: growth patterns
- Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
- SPTCL: diagnostic criteria
- Cutaneous gamma delta T-cell lymphoma
- Subcutaneous lymphomas
- Other primary cutaneous T-cell lymphomas
- Cutaneous CD4+ small/medium T-cell lymphoproliferative disorder
- Cutaneous CD4+ small/medium T-cell LPD (1)
- CD4+ SMT-LPD: phenotype
- Cutaneous CD4+ small/medium T-cell LPD (2)
- Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder
- Primary cutaneous acral CD8+ T-cell LPD
- Inborn error of immunity (IEI)-associated lymphoproliferative disorder
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (Berti lymphoma)
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- JAK2 overactivation
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- CD8+ epidermotropic infiltrate – differential diagnosis
- Differential diagnosis (5)
- Cutaneous gamma/delta T-cell lymphoma
- Primary cutaneous peripheral T-cell lymphomas
- Diagnostic approach to cutaneous lymphomas
Topics Covered
- Introduction to lymphomas and cutaneous T-cell lymphomas
- Classification
- Epidemiology
- Disease entities
- Clinical and pathological presentation
- Diagnosis
- Role of immunohistochemistry and molecular analysis of clonality
- Prognosis
- Therapeutic Aspects
Talk Citation
Kempf, W. (2024, September 30). Cutaneous T-cell lymphomas [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/ERZM4079.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Werner Kempf has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
It is my pleasure
to give a lecture
on cutaneous T-cell lymphomas.
My name is Werner Kempf.
I'm the co-director
of Kempf and Pfaltz
Histologische Diagnostik,
a pathology laboratory here
in Zurich, Switzerland,
and professor at the
Department of Dermatology
at the University of Zurich.
0:34
Lymphocytes are the cells
in the immune system
which are present in the blood
as part of the compartment
of white blood cells
in organs of the
lymphatic system,
particularly in the lymph nodes,
as well as in other organs.
For example, the skin.
There are three main
types of lymphocytes:
B cells, T cells, and
natural killer cells.
1:01
Lymphomas are neoplastic
proliferations of lymphocytes.
They may either
originate in lymph nodes
and called nodal lymphomas,
or in other body sites and
called extranodal lymphomas.
Actually, lymphomas are one of
the most common form of cancer,
so two major groups of
lymphomas are distinguished,
Hodgkin lymphoma and
non-Hodgkin lymphomas.
In the lymph nodes,
most lymphomas
originate from B cells,
whereas in the skin,
most lymphomas
originate from T cells.
Lymphomas span a broad
spectrum of neoplasias,
which differ in regard to
their clinical manifestation,
their histological
features, genetic changes,
as well as the prognosis.